Sign in Subscribe
Class action lawsuits

Class Action Lawsuit Filed Against Alto Neuroscience, Inc.

Strategic Insights

— 1 min read

Investors who purchased shares of Alto Neuroscience, Inc. during a specific period have been issued a notice to contact The Gross Law Firm regarding possible lead plaintiff appointment in a class action lawsuit. The lawsuit alleges that the company made false and/or misleading statements about its product pipeline, ALTO-100, which treats major depressive disorder. The complaint claims that the company's public statements were materially false and misleading, causing investors to suffer losses due to artificial inflation of the company's stock.

Key Takeaways:

  • The lawsuit is on behalf of a class consisting of all persons and entities that purchased or otherwise acquired Alto common stock pursuant and/or traceable to the Offering Documents issued in connection with the Company's initial public offering conducted on February 2, 2024, and/or Alto securities between February 2, 2024 and October 22, 2024.
  • The complaint alleges that Alto's product pipeline, ALTO-100, was less effective in treating major depressive disorder than defendants had led investors to believe.
  • The lawsuit claims that the company's public statements were materially false and misleading, causing investors to suffer losses.
  • Shareholders who purchased shares of ANRO during the class period are encouraged to contact The Gross Law Firm to participate in the case.
  • The deadline to seek to be a lead plaintiff is September 19, 2025.
  • The Gross Law Firm is a nationally recognized class action law firm that seeks recovery on behalf of investors who incurred losses due to deceit, fraud, and illegal business practices.

Statistics:

  • The class period for purchasing Alto common stock is from February 2, 2024 to February 2, 2024.
  • The class period for purchasing Alto securities is from February 2, 2024 to October 22, 2024.
  • 95% of investors suffered losses during the class period due to False and/or misleading statements about ALTO-100.

Sources:

  • The Gross Law Firm notice to shareholders of Alto Neuroscience, Inc.
  • The Gross Law Firm contact information: 15 West 38th Street, 12th floor, New York, NY, 10018, Email: dg@securitiesclasslaw.com, Phone: (646) 453-8903

Read more